Elevance Health is reaffirming full-year 2026 shareholders’ Earnings guidance of at least $20.10 per diluted share, including approximately $6.90 per diluted share of net unfavorable items. The company’s outlook gives investors stated targets for adjusted earnings and the benefit expense ratio as management meets with analysts.

Key Highlights

  • Adjusted shareholders’ earnings guidance remains at least $27.00 per diluted share for full year 2026.
  • Elevance Health reaffirmed full-year 2026 shareholders’ earnings guidance of at least $20.10 per diluted share.
  • The outlook is subject to risks including healthcare cost trends, enrollment changes, regulatory developments, Cybersecurity incidents and competitive pressures.

Elevance Health, Inc. (NYSE: ELV) is reaffirming full-year 2026 shareholders’ earnings guidance of at least $20.10 per diluted share.

Adjusted Earnings and Cost Ratio Targets

The guidance applies to full year 2026. Elevance Health said the outlook excludes adjustment items beyond those reported in its second quarter 2026 earnings. Benefit expense ratio guidance remains 90.2%, with a range of plus or minus 50 basis points.

Forward-Looking Guidance Carries Stated Risks

The earnings and benefit expense targets are forward-looking statements, and Elevance Health cautioned that actual financial performance may differ from those projections. The company identified healthcare cost and utilization trends, enrollment changes, premium-rate sufficiency and changes in healthcare, insurance and pharmacy regulations among the uncertainties affecting its outlook. Risks also include cybersecurity incidents, information-system failures, Medicare and Medicaid developments, provider contracting and competitive pressures. Elevance Health advised investors not to place undue reliance on the projections and said it does not undertake to update them except where required by law.